Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Kretzschmar, Mirjam E
Mikolajczyk, Rafael T
MetadataShow full item record
AbstractVaricella zoster virus (VZV) is primarily known for causing varicella in childhood, but can reactivate again as herpes zoster (HZ) after a period of latency, mainly in persons older than 50 years. Universal varicella vaccination was introduced in Germany in 2004, while HZ vaccination has not been recommended yet. We aimed to quantify the potential long-term effects of universal childhood varicella vaccination and HZ vaccination of the elderly on varicella and HZ incidence in Germany over a time horizon of 100 years, using a transmission model calibrated to pre-vaccination data and validated against early post-vaccination data. Using current vaccination coverage rates of 87% (64%) with one (two) varicella vaccine dose(s), the model predicts a decrease in varicella cases by 89% for the year 2015. In the long run, the incidence reduction will stabilize at about 70%. Under the assumption of the boosting hypothesis of improved HZ protection caused by exposure to VZV, the model predicts a temporary increase in HZ incidence of up to 20% for around 50 years. HZ vaccination of the elderly with an assumed coverage of 20% has only limited effects in counteracting this temporary increase in HZ incidence. However, HZ incidence is shown to decrease in the long-term by 58% as vaccinated individuals get older and finally reach age-classes with originally high HZ incidence. Despite substantial uncertainties around several key variables, the model's results provide valuable insights that support decision-making regarding national VZV vaccination strategies.
CitationCurrent and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination. 2016, 12 (7):1766-76 Hum Vaccin Immunother
AffiliationHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
- Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
- Authors: Marchetti S, Guzzetta G, Flem E, Mirinaviciute G, Scalia Tomba G, Manfredi P
- Issue date: 2018 Feb 14
- Distribution of Health Effects and Cost-effectiveness of Varicella Vaccination are Shaped by the Impact on Herpes Zoster.
- Authors: van Lier A, Lugnér A, Opstelten W, Jochemsen P, Wallinga J, Schellevis F, Sanders E, de Melker H, van Boven M
- Issue date: 2015 Oct
- Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England.
- Authors: van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay N
- Issue date: 2011 Mar 16
- The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom.
- Authors: van Hoek AJ, Melegaro A, Gay N, Bilcke J, Edmunds WJ
- Issue date: 2012 Feb 1
- The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting.
- Authors: Sauboin C, Holl K, Bonanni P, Gershon AA, Benninghoff B, Carryn S, Burgess MA, Wutzler P
- Issue date: 2019 Feb 6